Yulia Rodina

1.0k total citations
20 papers, 100 citations indexed

About

Yulia Rodina is a scholar working on Immunology, Hematology and Genetics. According to data from OpenAlex, Yulia Rodina has authored 20 papers receiving a total of 100 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 6 papers in Hematology and 6 papers in Genetics. Recurrent topics in Yulia Rodina's work include Immunodeficiency and Autoimmune Disorders (14 papers), Blood disorders and treatments (5 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Yulia Rodina is often cited by papers focused on Immunodeficiency and Autoimmune Disorders (14 papers), Blood disorders and treatments (5 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Yulia Rodina collaborates with scholars based in Russia, United States and Belarus. Yulia Rodina's co-authors include Anna Shcherbina, Alexey Maschan, Elena Deripapa, Д. С. Абрамов, Michael Maschan, Dmitry Pershin, Alexandra Laberko, Anna Roppelt, А.П. Продеус and Dmitry Balashov and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Journal of Allergy and Clinical Immunology.

In The Last Decade

Yulia Rodina

14 papers receiving 96 citations

Peers

Countries citing papers authored by Yulia Rodina

Since Specialization

Citations

This map shows the geographic impact of Yulia Rodina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yulia Rodina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yulia Rodina more than expected).

Fields of papers citing papers by Yulia Rodina

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yulia Rodina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yulia Rodina. The network helps show where Yulia Rodina may publish in the future.

Co-authorship network of co-authors of Yulia Rodina

This figure shows the co-authorship network connecting the top 25 collaborators of Yulia Rodina. A scholar is included among the top collaborators of Yulia Rodina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yulia Rodina. Yulia Rodina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Harmonizing TREC Thresholds in Newborn Screening for SCID: Insights From Russian Validation Cohort 2025 ·Journal of Clinical Laboratory Analysis ·Andrey V. Marakhonov, (unknown), Sergey S. Larin, (unknown), (unknown), Anna Mukhinа, Yulia Rodina, (unknown), (unknown), (unknown), (unknown), Р. А. Зинченко, (unknown), Anna Shcherbina, Sergey I. Kutsev	0
2	Genetic Characteristics of a Large Pediatric Cohort of Patients with Inborn Errors of Immunity: Single-Center Experience 2024 ·Journal of Clinical Immunology ·(unknown), (unknown), Anna Mukhinа, Yulia Rodina, (unknown), Dmitry Pershin, (unknown), (unknown), (unknown), Галина Новичкова, Anna Shcherbina	1
3	A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis 2024 ·Clinical Immunology ·V. Koneti Rao, Anna Šedivá, Virgil A. S. H. Dalm, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina, Antonino Trizzino, (unknown), (unknown), (unknown), Sharon Webster, Julia Körholz, Vassilios Lougaris, Yulia Rodina, Niall Conlon, Tanya Coulter, (unknown), Anurag Relan, Gülbû Uzel	1
4	Combined therapy with IL-1 and JAK inhibitors in a patient with the NLRP1 gene mutation and a complex inflammatory phenotype 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Dmitry Pershin, Yulia Rodina, (unknown), G. А. Novichkova, Ivona Aksentijevich, Anna Shcherbina	2
5	Novel LYST Variants Lead to Aberrant Splicing in a Patient with Chediak–Higashi Syndrome 2024 ·Genes ·(unknown), (unknown), (unknown), (unknown), Yulia Rodina, Michael Maschan, Anna Shcherbina, (unknown)	0
6	Interim analysis: Open-label extension study of leniolisib for patients with APDS 2023 ·Journal of Allergy and Clinical Immunology ·V. Koneti Rao, (unknown), Anna Šedivá, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina, Virgil A. S. H. Dalm, Antonino Trizzino, (unknown), Sharon Webster, (unknown), Julia Körholz, Vassilios Lougaris, Yulia Rodina, (unknown), (unknown), Anurag Relan, Steven M. Holland, Michael J. Lenardo, (unknown)	20
7	BCG Infection in Patients With Inborn Errors of Immunity Receiving the Russian BCG Strain 2022 ·The Journal of Allergy and Clinical Immunology In Practice ·Alexandra Laberko, (unknown), (unknown), Anna Roppelt, Anna Mukhinа, Yulia Rodina, Dmitry Pershin, Aristine Cheng, Michail S. Lionakis, (unknown), (unknown), (unknown), Галина Новичкова, Anna Shcherbina	4
8	Cancer‐causing MAP2K1 mutation in a mosaic patient with cardio‐facio‐cutaneous syndrome and immunodeficiency 2022 ·Human Mutation ·(unknown), (unknown), Irina Mersiyanova, (unknown), Dmitry Pershin, (unknown), Yulia Rodina, (unknown), Michael Maschan, Anna Shcherbina	3
9	Interim Analysis of Safety and Hematological Parameters of an Ongoing Long-Term Open-Label Extension Study of Investigational PI3Kδ Inhibitor Leniolisib for Patients with Activated PI3K Delta Syndrome (APDS) through December 2021 2022 ·Blood ·V. Koneti Rao, Sharon Webster, Anna Šedivá, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina, Virgil A. S. H. Dalm, Antonino Trizzino, (unknown), (unknown), (unknown), (unknown), Julia Körholz, Vassilios Lougaris, Yulia Rodina, Klaus Kucher, (unknown), (unknown), (unknown)	5
10	Rituximab and Abatacept Are Effective in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies 2021 ·Frontiers in Immunology ·Yulia Rodina, Elena Deripapa, (unknown), Anna Mukhinа, Anna Roppelt, (unknown), Alexandra Laberko, (unknown), Д. С. Абрамов, (unknown), G. А. Novichkova, Anna Shcherbina	3
11	BCG-Related Inflammatory Syndromes in Severe Combined Immunodeficiency After TCRαβ+/CD19+ Depleted HSCT 2020 ·Journal of Clinical Immunology ·Alexandra Laberko, (unknown), Yulia Rodina, Д. С. Абрамов, Д. М. Коновалов, (unknown), (unknown), Dmitry Pershin, (unknown), Michael Maschan, Alexei Maschan, Dmitry Balashov, Anna Shcherbina	9
12	Efficacy and Safety of Octanorm (cutaquig ^® ) in Adults with Primary Immunodeficiencies with Predominant Antibody Deficiency: A Prospective, Open-Label Study 2020 ·Immunotherapy ·(unknown), Yulia Rodina, (unknown), Арег А. Тотолян, Irina A. Tuzankina	6
13	Efficacy of romiplostim in treatment of thrombocytopenia in children with Wiskott–Aldrich syndrome 2020 ·British Journal of Haematology ·(unknown), (unknown), Elena Deripapa, Yulia Rodina, Anna Roppelt, Dmitry Pershin, Sergey S. Larin, K. A. Voronin, Alexey Maschan, G. А. Novichkova, Anna Shcherbina	10
14	NIJMEGEN SYNDROME IN CHILDREN: CLINICAL AND LABORATORY CHARACTERISTICS AND EVALUATION OF VARIOUS THERAPIES EFFICACY 2018 ·PEDIATRIA Journal named after G N SPERANSKY ·Elena Deripapa, Yulia Rodina, Alexandra Laberko, Dmitry Balashov, (unknown), (unknown), (unknown), (unknown), Д. С. Абрамов, (unknown), (unknown), А.П. Продеус, Michael Maschan, Alexey Maschan, Anna Shcherbina	0
15	APPROACHES TO THE DIAGNOSIS AND THERAPY OF INTERSTITIAL LYMPHOCYTIC LUNG DISEASE IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY STATES 2018 ·PEDIATRIA Journal named after G N SPERANSKY ·Yulia Rodina, (unknown), Д. С. Абрамов, Anna Shcherbina	2
16	Therapy features of interstitial lymphocytic lung disease (ILLD) in patients with immune dysregulation syndromes: case report 2018 ·Pediatric Hematology/Oncology and Immunopathology ·Yulia Rodina, (unknown), (unknown), (unknown), (unknown), (unknown), Д. С. Абрамов, Elena Deripapa	1
17	Prospective Study of a Cohort of Russian Nijmegen Breakage Syndrome Patients Demonstrating Predictive Value of Low Kappa-Deleting Recombination Excision Circle (KREC) Numbers and Beneficial Effect of Hematopoietic Stem Cell Transplantation (HSCT) 2017 ·Frontiers in Immunology ·Elena Deripapa, Dmitry Balashov, Yulia Rodina, Alexandra Laberko, (unknown), (unknown), (unknown), Д. С. Абрамов, (unknown), (unknown), А.П. Продеус, Michael Maschan, Alexey Maschan, Anna Shcherbina	25
18	Chediak-Higashi syndrome (Review of literature and clinical case reports) 2016 ·Pediatric Hematology/Oncology and Immunopathology ·Yulia Rodina, (unknown), Dmitry Balashov, (unknown), Anna Shcherbina	0
19	Pharmacoeconomic analysis of intravenous immunoglobulin replacement therapy in patients with primary humoral immunodeficiencies 2016 ·Pediatric Hematology/Oncology and Immunopathology ·И. Н. Смирнова, Yulia Rodina, Elena Deripapa, Anna Roppelt, Alexandra Laberko, (unknown), (unknown), Anna Shcherbina	1
20	Molecular Characteristics, Clinical and Immunologic Manifestations of 11 Children with Omenn Syndrome in East Slavs (Russia, Belarus, Ukraine) 2015 ·Journal of Clinical Immunology ·Svetlana Sharapova, (unknown), (unknown), Irina Kondratenko, Larysa Kostyuchenko, Yulia Rodina, (unknown), Анастасія Бондаренко, Л.И. Чернышова, (unknown), (unknown), (unknown), Olga Aleinikova	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact